Middle East Healthcare Co.’s (Saudi German Health) earnings rose to SAR 282 million by the end of 2024, compared with SAR 17 million a year earlier.
Item | 2023 | 2024 | Change |
---|---|---|---|
Revenues | 2,653.17 | 2,882.82 | 8.7 % |
Gross Income | 1,014.41 | 1,113.90 | 9.8 % |
Operating Income | 323.97 | 440.93 | 36.1 % |
Net Income | 17.04 | 282.00 | 1554.9 % |
Average Shares | 92.04 | 92.04 | - |
Earnings Per Share before unusual items (Riyals) | 2.04 | 2.36 | 15.5 % |
EPS (Riyals) | 0.19 | 3.06 | 1554.9 % |
This annual profit growth was driven by the elevated revenues, thanks to the higher number of inpatient and outpatient visits. This was supported by the group's expanded capacity, with more operational beds and clinics added in 2024, compared to 2023.
The rise in business volumes with the Ministry of Health, insurance companies, and cash-paying customers further contributed to Saudi German Health’s 2024 revenue increase.
In 2024, Saudi German Health recorded a capital gain of SAR 19.6 million from the sale of a land plot in Riyadh.
Item | Q4 2023 | Q4 2024 | Change |
---|---|---|---|
Revenues | 719.81 | 748.88 | 4.0 % |
Gross Income | 293.96 | 282.08 | (4.0 %) |
Operating Income | 68.62 | 101.69 | 48.2 % |
Net Income | 44.37 | 107.14 | 141.5 % |
Average Shares | 92.04 | 92.04 | - |
Earnings Per Share before unusual items (Riyals) | 0.48 | 0.67 | 39.1 % |
EPS (Riyals) | 0.48 | 1.16 | 141.5 % |
Item | Q3 2024 | Q4 2024 | Change |
---|---|---|---|
Revenues | 732.07 | 748.88 | 2.3 % |
Gross Income | 292.90 | 282.08 | (3.7 %) |
Operating Income | 115.88 | 101.69 | (12.2 %) |
Net Income | 61.74 | 107.14 | 73.5 % |
Average Shares | 92.04 | 92.04 | - |
Earnings Per Share before unusual items (Riyals) | 0.67 | 0.67 | (0.1 %) |
EPS (Riyals) | 0.67 | 1.16 | 73.5 % |
As for Q4 2024, the company reported a net profit of SAR 107.14 million, marking a 141.5% uptick from SAR 44.37 million in the fourth quarter of 2023.
Sequentially, the bottom line jumped by 73.5% from SAR 61.74 million in Q3 2024.
Shareholders’ equity, after minority interest, stood at SAR 1.62 billion by the end of 2024, up from SAR 1.31 billion a year earlier.
Company | Estimated | Actual | Change |
---|---|---|---|
SAUDI GERMAN HEALTH | 64.76 | 107.14 | 65.4 % |
MARAFIQ | 37.00 | (276.97) | (848.6 %) |
Company | Estimated | Actual | Change |
---|---|---|---|
SAUDI GERMAN HEALTH | 64.76 | 107.14 | 65.4 % |
Company | Estimated | Actual | Change |
---|---|---|---|
MARAFIQ | 37.00 | (276.97) | (848.6 %) |
Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.
Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}